Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 56.9%

Neg 56.9% Neu 0% Pos 0%

Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.

Comments

No comments yet. Be the first!